Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.54 |
| ▸ | AKT2 | P31751 | 9/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868156 | 0.89 | AKT1 (0.60) | AKT1AKT2 | |
| SCHEMBL538965 | 0.86 | AKT1 (0.60) | AKT1AKT2 | |
| SCHEMBL867218 | 0.84 | AKT1 (0.59) | AKT1AKT2 | |
| SCHEMBL362645 | 0.84 | AKT1 (0.61) | AKT1AKT2 | |
| SCHEMBL867935 | 0.81 | AKT1 (0.55) | AKT1AKT2 | |
| SCHEMBL539102 | 0.81 | AKT1 (0.54) | AKT1AKT2 | |
| SCHEMBL868035 | 0.80 | AKT1 (0.61) | AKT1AKT2 | |
| SCHEMBL867146 | 0.80 | AKT1 (0.57) | AKT1AKT2 | |
| SCHEMBL866809 | 0.80 | AKT1 (0.57) | AKT1 | |
| SCHEMBL4068385 | 0.80 | PTGS1 (0.39) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077810-A1 | Inhibitors Of AKT Activity | MERCK SHARP & DOHME LLC | 2012-03-29 | — | — | US | claimed |
| US-8691825-B2 | Inhibitors of AKT activity | MERCK SHARP & DOHME CORP. (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691825-B2 | Inhibitors of AKT activity | MERCK SHARP & DOHME CORP. (US) | 2014-04-08 | — | — | US | disclosed |
| US-20120077810-A1 | Inhibitors Of AKT Activity | MERCK SHARP & DOHME LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120077810-A1 | Inhibitors Of AKT Activity | MERCK SHARP & DOHME LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120077810-A1 | Inhibitors Of AKT Activity | MERCK SHARP & DOHME LLC | 2012-03-29 | — | — | US | disclosed |
| EP-2413932-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114780-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077810-A1 | Inhibitors Of AKT Activity | PIK3CA, PIK3CD, PIK3CB | AKT1 11/4885AKT2 7/4885CHRM1 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.